NASDAQ$COLL
Collegium Pharmaceutical Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Collegium reported a net loss and total net product revenues decreased compared to the same quarter last year.
Collegium Pharmaceutical reported first quarter 2022 financial results, which included a net loss of $13.1 million and total net product revenues of $83.8 million. The company completed the acquisition of BDSI and is on track to exceed targeted run rate synergies of at least $75 million. They also resolved all opioid-industry litigation and reaffirmed their 2022 financial guidance.
- Generated net revenue of $83.8 million
- Completed BDSI Acquisition; On Track to Exceed Targeted Run Rate Synergies of at Least $75 Million
- Resolved All Opioid-Industry Litigation
- Grew Belbuca and Xtampza ER total prescriptions 4% and 3%, respectively, over the first quarter of 2021
Headline financials
Revenue & EPS history
Collegium · Revenue · Quarterly
$83.8M
Revenue by segment
Collegium · $133M total across 3 segments · Q3 2023
- Nucynta Franchise$47.5M—35.8%
- Belbuca$45.4M—34.2%
- Xtampza ER$39.8M—30.0%
Forward guidance
The Company reaffirms financial guidance for the full year 2022, originally provided on April 5, 2022: ●Total product revenues are expected in the range of $450.0 million to $465.0 million, up approximately 65% at the midpoint compared to net product revenue of $276.9 million in 2021; ●Total adjusted operating expenses, which excludes stock-based compensation expense and acquisition related expenses, are expected in the range of $130.0 million to $140.0 million; and ●Total adjusted EBITDA which excludes stock-based compensation and acquisition related expenses, is expected in the range of $235.0 million to $250.0 million.
Tailwinds
- Total product revenues are expected in the range of $450.0 million to $465.0 million
- Revenues are expected to be up approximately 65% at the midpoint compared to net product revenue of $276.9 million in 2021
- Total adjusted operating expenses are expected in the range of $130.0 million to $140.0 million
- Total adjusted EBITDA is expected in the range of $235.0 million to $250.0 million.
- On track to exceed targeted run rate synergies of at least $75 million
Headwinds
- Unable to predict the timing and amount of items that would be included in such a reconciliation, including, but not limited to, stock-based compensation expense.
- The impact of the COVID-19 pandemic on our ability to conduct our business, reach our customers, and supply the market with our products
- Our ability to commercialize and grow sales of our products
- The success of competing products that are or become available
- The outcome of any patent infringement, opioid-related or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+2.6%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+2.2%
Avg return
30 days after
61%
28 / 46 earnings
Positive
+31.2%
Q3 2019
Best reaction
-17.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | -2.2% | -8.9% | |
| Q4 2025 | -3.5% | -12.6% | -29.1% | |
| Q3 2025 | +4.4% | +16.5% | +17.8% | |
| Q1 2025 | +5.9% | +6.6% | +10.7% | |
| Q4 2024 | +2.2% | +0.2% | +4.5% | |
| Q3 2024 | -6.8% | -9.0% | -13.1% | |
| Q2 2024 | +2.5% | +5.9% | +7.3% | |
| Q1 2024 | -17.2% | -12.5% | -12.8% | |
| Q4 2023 | +14.5% | +15.8% | +25.1% | |
| Q3 2023 | +4.6% | +10.8% | +23.0% | |
| Q2 2023 | +6.8% | +9.5% | +7.9% | |
| Q1 2023 | +3.6% | +6.4% | -2.2% | |
| Q4 2022 | +1.7% | +0.5% | -10.0% | |
| Q3 2022 | +6.9% | +11.9% | +30.6% | |
| Q2 2022 | +11.4% | +7.2% | -1.0% | |
| Q1 2022 | +1.7% | +10.0% | +15.9% | |
| Q4 2021 | -14.0% | -17.7% | -14.1% | |
| Q3 2021 | -5.3% | +1.0% | -12.5% | |
| Q2 2021 | -17.6% | -23.7% | -19.2% | |
| Q1 2021 | +3.6% | -0.3% | -1.8% | |
| Q4 2020 | -9.6% | -14.1% | -8.8% | |
| Q3 2020 | +2.2% | +4.3% | +1.9% | |
| Q2 2020 | +6.6% | +13.4% | +16.4% | |
| Q1 2020 | +9.4% | +16.2% | +0.3% | |
| Q4 2019 | +5.2% | -1.5% | -27.4% | |
| Q3 2019 | +31.2% | +38.5% | +53.5% | |
| Q2 2019 | +4.0% | +9.6% | +0.9% | |
| Q1 2019 | +5.6% | -2.9% | -18.0% | |
| Q4 2018 | +18.5% | +22.4% | +2.0% | |
| Q3 2018 | -0.4% | +10.8% | +23.1% | |
| Q2 2018 | -5.7% | -2.0% | -15.7% | |
| Q1 2018 | +11.6% | +8.6% | +9.7% | |
| Q4 2017 | +17.9% | +6.3% | -11.9% | |
| Q3 2017 | +25.8% | +44.7% | +75.2% | |
| Q2 2017 | -4.2% | -0.1% | -2.4% | |
| Q1 2017 | +12.5% | +11.5% | +28.0% | |
| Q4 2016 | +7.9% | +7.4% | -34.6% | |
| Q3 2016 | +7.9% | +1.8% | -0.1% | |
| Q2 2016 | -13.1% | -9.7% | -23.8% | |
| Q1 2016 | -3.0% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | -10.4% | — | — | |
| Q2 2015 | -4.3% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q1 2014 | -0.8% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro